Retrogenix provides the leading solution for receptor and membrane target deconvolution. They specialise in discovering which human plasma membrane proteins are targeted by antibodies, proteins, small molecules and viruses. This enables the identification of high quality, unexploited drug targets and significantly improves the rates of drug research and development.
The Queen’s Award for Innovation was awarded to Retrogenix in recognition of its success with this fascinating and unique human cell microarray technology.
Dr Jim Freeth, Managing Director of Retrogenix, said: “it is an honour to receive the Queens’ Awards for Innovation. The novel approach and high success rate of our human cell microarray technology has allowed us to develop great working relationships with many of the world’s major pharmaceutical companies and leading academic groups, advancing their research and development and supporting breakthroughs in medical research and pharmaceutical discovery.”
With this highly versatile technology Retrogenix are looking forward to continuing their success and building further relationships and ongoing collaborations. Executive Director, Jo Soden “We have a fantastic team here at Retrogenix and we continue to expand the company and invest in innovation in order to further increase the value of our technology.”
For further information: http://ow.ly/Sz64N